Drug Landscape ›
NaCl infusion ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 18
Most-reported reactions
Pancytopenia — 3 reports (16.67%) Diarrhoea — 2 reports (11.11%) Fall — 2 reports (11.11%) Febrile Neutropenia — 2 reports (11.11%) Infusion Related Reaction — 2 reports (11.11%) Nausea — 2 reports (11.11%) Vomiting — 2 reports (11.11%) Acute Respiratory Failure — 1 report (5.56%) Ageusia — 1 report (5.56%) Aortic Valve Sclerosis — 1 report (5.56%)
Source database →
NaCl infusion in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is NaCl infusion approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for NaCl infusion in United States?
Dextra Fertility Clinic is the originator. The local marketing authorisation holder may differ — check the official source linked above.